RecruitingNot ApplicableNCT07046429

Affect of Melatonin on Sleep and Cognition in Cirrhosis

Effect of Supplemental Nightly Melatonin On REM and Cognition in Hepatic Encephalopathy (SNORE-HE) Trial


Sponsor

Weill Medical College of Cornell University

Enrollment

18 participants

Start Date

Aug 5, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this clinical trial is to learn the affect of melatonin on sleep, cognitive function, and quality of life (QoL) in patients with cirrhosis and a complication called hepatic encephalopathy (HE). The main questions this study aims to answer are: * Does taking melatonin increase REM sleep, an important part of healthy sleep that is reduced in cirrhosis? * Does taking melatonin improve cognitive function and reported QoL? This is a pilot study, where participants will: * take one month of melatonin, followed by one month of thiamine, which is another supplement but is not suspected to impact sleep significantly. * Undergo cognitive testing and take surveys * Wear a commercial wearable sleep tracker * Have a formal sleep study and salivary melatonin collection at the end of taking each supplement at our sleep center Participants will be blinded, and neither they nor the researchers will know which supplement they are taking first and which they are taking second. They will also be randomized, with half starting with melatonin and the other half starting with thiamine.


Eligibility

Min Age: 18 Years

Inclusion Criteria5

  • Cirrhosis with clinically significant portal hypertension or decompensation defined by Baveno VII criteria \[de Franchis R et al 2022\]
  • Adults over age 18
  • CHE (defined by PHES≤ -4) or previously diagnosed HE
  • Disturbed sleep, with Pittsburgh Sleep Quality Index (PSQI) ≥5
  • Possession of a "smart phone" with Bluetooth capability and ability to download the Oura application (Apple iOS version 14.0 or greater or Android version 8.0 or higher)

Exclusion Criteria7

  • Use of melatonin regularly (3x per week) if unable/unwilling to discontinue for the study
  • Inability provide informed consent
  • Heavy current alcohol use (\>7 drinks weekly for women and 14 drinks weekly for men)'
  • \-- Body mass index \>40
  • Known prior sleep disorder including obstructive sleep apnea
  • Use of other prescription neuromodulating sleep aides
  • Self-reported pregnancy during study screening, as sleep physiology is different in this population

Interventions

DIETARY_SUPPLEMENTMelatonin tablet 3 mg once daily

Participants will be instructed to take 3 mg regular acting (not orally dissolving) melatonin 30 minutes before their anticipated bedtime, nightly for the 30 days preceding analysis of study endpoints.

DIETARY_SUPPLEMENTThiamine

Participants will be instructed to take 100 mg regular acting (not orally dissolving) thiamine 30 minutes before their anticipated bedtime, nightly for the 30 days preceding analysis of study endpoints.


Locations(1)

NewYork-Presbyterian/Weill Cornell Medical Center

New York, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07046429


Related Trials